Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report

Bristol-Myers Squibb Company Stock price

Equities

BMY

US1101221083

Pharmaceuticals

Delayed Nyse
Other stock markets
 04:00:02 2023-09-26 pm EDT 		Intraday chart for Bristol-Myers Squibb Company 5-day change 1st Jan Change
58.54 USD -1.05% -0.15% -18.64%
Sep. 22 Bristol-Myers Squibb Says Cancer Drug Opdivo Met Primary Endpoint in Phase 3 Trial MT
Sep. 22 Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer CI

Financials (USD)

Sales 2023 * 44,852 M Sales 2024 * 46,595 M Capitalization 124 B
Net income 2023 * 7,930 M Net income 2024 * 8,648 M EV / Sales 2023 *
3,30x
Net Debt 2023 * 24,326 M Net Debt 2024 * 16,292 M EV / Sales 2024 *
3,00x
P/E ratio 2023 *
15,1x
P/E ratio 2024 *
12,2x
Employees -
Yield 2023 *
3,87%
Yield 2024 *
4,03%
Free-Float71.40%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Bristol-Myers Squibb Says Cancer Drug Opdivo Met Primary Endpoint in Phase 3 Trial MT
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer CI
Bristol-Myers Squibb Keeps Quarterly Dividend of $0.57 Per Share, Payable Nov. 1 to Stockholders on Oct. 6 MT
Bristol-Myers Squibb Company Declares Quarterly Dividend, Payable on November 1, 2023 CI
BeiGene regains rights for cancer drug after Novartis deal termination RE
Bristol-Myers Squibb, Samsung Biologics Expand Manufacturing Agreement for Cancer Drug Substance MT
TD Cowen Adjusts Bristol-Myers Squibb's Price Target to $67 From $80, Keeps Market Perform Rating MT
Transcript : Bristol-Myers Squibb Company - Special Call CI
Bristol Myers plans to double experimental treatments to expand research pipeline RE
ROME Therapeutics, Inc. announced that it has received $149 million in funding from a group of investors CI
Transcript : Bristol-Myers Squibb Company Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 08:00 AM CI
AstraZeneca Partners with Futurize to Launch Healthcare Startups Incubator in Africa MT
Bristol Myers Squibb Announces Results from Phase 2 Study Evaluating BMS-986278 CI
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit RE
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans RE
More news

Analyst Recommendations on Bristol-Myers Squibb Company

TD Cowen Adjusts Bristol-Myers Squibb's Price Target to $67 From $80, Keeps Market Perform Rating MT
Jefferies Trims Bristol-Myers Squibb's Price Target to $61 From $62, Hold Rating Maintained MT
Credit Suisse Lowers Bristol-Myers Squibb's PT to $62 From $66, Neutral Rating Kept MT
Morgan Stanley Cuts Bristol-Myers Squibb's Price Target to $57 From $59, Underweight Rating Kept MT
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $81 From $89, Buy Rating Kept MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023 BU
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer AQ
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer BU
Bristol Myers Squibb Announces Dividend BU
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance PR
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol-Myers Squibb annonce que l'anticancéreux Opdivo a atteint le critère principal de l'essai de phase 3
Bristol Myers Squibb annonce que le régime périopératoire d'Opdivo (nivolumab) néoadjuvant et de chimiothérapie suivi d'Opdivo adjuvant améliore significativement la survie sans événement chez les patients atteints d'un cancer du poumon non à petites cellules résécable.
Bristol Myers : données de phase III positives pour Opdivo
ANALYSEN DES TAGES von Dow Jones Newswires (21.09.2023)
Bristol-Myers Squibb Company déclare un dividende trimestriel, payable le 1er novembre 2023
More news

Quotes and Performance

1 day-1.05%
1 week-0.15%
Current month-5.04%
1 month-5.03%
3 months-9.65%
6 months-14.00%
Current year-18.64%
More quotes

Highs and lows

1 week
58.52
Extreme 58.52
59.46
1 month
58.33
Extreme 58.33
63.41
Current year
58.33
Extreme 58.33
75.18
1 year
58.33
Extreme 58.33
81.44
3 years
53.22
Extreme 53.22
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Giovanni Caforio CEO
 Chief Executive Officer 58 2015
David Elkins DFI
 Director of Finance/CFO 54 2019
Cari Gallman CMP
 Compliance Officer - -
Members of the board TitleAgeSince
Giovanni Caforio CHM
 Chairman 58 2017
Peter Arduini BRD
 Director/Board Member 58 2016
David Elkins DFI
 Director of Finance/CFO 54 2019
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 189 M$ -4.95% -
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
4.01% 30 M$ +5.67% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
23-09-26 58.54 -1.05% 9,380,648
23-09-25 59.16 +0.44% 7,005,969
23-09-22 58.90 -0.30% 8,191,466
23-09-21 59.08 +0.51% 9,597,339
23-09-20 58.78 +0.26% 8,699,641

Delayed Quote Nyse, September 26, 2023 at 04:00 pm EDT

More quotes

Company Profile

More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
59.16USD
Average target price
72.47USD
Spread / Average Target
+22.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-18.64% 124 B $
SANOFI Stock Sanofi
+14.40% 136 B $
AMGEN INC. Stock Amgen Inc.
+2.44% 143 B $
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-12.02% 93 239 M $
GSK PLC Stock GSK plc
+6.58% 75 971 M $
ALLERGAN PLC Stock Allergan plc
+0.97% 63 659 M $
PFIZER, INC. Stock Pfizer, Inc.
-36.77% 186 B $
DAIICHI SANKYO CO., LTD. Stock Daiichi Sankyo Co., Ltd.
-5.76% 53 913 M $
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
+16.86% 49 801 M $
BAYER AG Stock Bayer AG
-5.47% 48 190 M $
Other Pharmaceuticals
  1. Markets
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer